{
    "hands_on_practices": [
        {
            "introduction": "Cholinergic signaling does more than simply transmit fast signals; it profoundly modulates neuronal excitability. One classic mechanism is the suppression of the muscarine-sensitive potassium current, or M-current, which makes a neuron more responsive to other inputs. This practice exercise allows you to quantify how activating M1 muscarinic receptors changes a neuron's fundamental electrical properties, specifically its input resistance ($R_{in}$) and membrane time constant ($\\tau_m$), providing a concrete link between receptor signaling and cellular function .",
            "id": "5007941",
            "problem": "A cortical layer $5$ pyramidal neuron at rest is modeled as a single, isopotential compartment whose membrane contains multiple ion channel populations that behave linearly near rest and act as conductances in parallel. The neuron has a baseline whole-cell leak conductance of $8\\ \\mathrm{nS}$ and a resting muscarine-sensitive potassium current (M-current) conductance of $12\\ \\mathrm{nS}$. The total membrane capacitance is $150\\ \\mathrm{pF}$. Acetylcholine (ACh) acting on the M$1$ muscarinic acetylcholine receptor (M$1$) suppresses the M-current conductance by $50\\%$ at rest, without altering the leak conductance or the membrane capacitance. Treat the resting membrane as linear around the holding potential.\n\nCompute the change (new minus baseline) in the neuron's input resistance and membrane time constant caused by this $50\\%$ suppression of the M-current at rest. Express the change in input resistance in megaohms and the change in membrane time constant in milliseconds. Round your answers to four significant figures.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective. The problem describes a standard single-compartment model of a neuron, a fundamental concept in computational neuroscience. The parameters provided—leak conductance ($g_L = 8\\ \\mathrm{nS}$), M-current conductance ($g_M = 12\\ \\mathrm{nS}$), and membrane capacitance ($C_m = 150\\ \\mathrm{pF}$)—are physiologically realistic for a cortical pyramidal neuron. The action of acetylcholine (ACh) in suppressing the M-current via muscarinic receptors is a well-established neuromodulatory mechanism. The problem is a straightforward application of circuit theory to a biophysical model, contains all necessary information, and is free of ambiguity. Therefore, the problem is deemed valid.\n\nThe neuron is modeled as a single, isopotential compartment where the ion channels act as conductances in parallel. The total membrane conductance, $g_{tot}$, is the sum of the individual conductances. The input resistance, $R_{in}$, is the reciprocal of the total conductance. The membrane time constant, $\\tau_m$, is the product of the input resistance and the membrane capacitance, $C_m$.\n\nThe baseline state (before ACh application) is characterized by the following parameters:\nBaseline leak conductance: $g_L = 8 \\times 10^{-9}\\ \\mathrm{S}$\nBaseline M-current conductance: $g_{M, \\text{base}} = 12 \\times 10^{-9}\\ \\mathrm{S}$\nMembrane capacitance: $C_m = 150 \\times 10^{-12}\\ \\mathrm{F}$\n\nThe total baseline conductance, $g_{tot, \\text{base}}$, is the sum of the leak and M-current conductances:\n$$g_{tot, \\text{base}} = g_L + g_{M, \\text{base}} = 8 \\times 10^{-9}\\ \\mathrm{S} + 12 \\times 10^{-9}\\ \\mathrm{S} = 20 \\times 10^{-9}\\ \\mathrm{S}$$\n\nThe baseline input resistance, $R_{in, \\text{base}}$, is the reciprocal of the total baseline conductance:\n$$R_{in, \\text{base}} = \\frac{1}{g_{tot, \\text{base}}} = \\frac{1}{20 \\times 10^{-9}\\ \\mathrm{S}} = 50 \\times 10^6\\ \\Omega = 50\\ \\mathrm{M\\Omega}$$\n\nThe baseline membrane time constant, $\\tau_{m, \\text{base}}$, is given by the product of the baseline input resistance and the membrane capacitance:\n$$\\tau_{m, \\text{base}} = R_{in, \\text{base}} \\cdot C_m = (50 \\times 10^6\\ \\Omega) \\cdot (150 \\times 10^{-12}\\ \\mathrm{F}) = 7500 \\times 10^{-6}\\ \\mathrm{s} = 7.5\\ \\mathrm{ms}$$\n\nUpon application of acetylcholine, the M-current conductance, $g_M$, is suppressed by $50\\%$. The new M-current conductance, $g_{M, \\text{new}}$, is:\n$$g_{M, \\text{new}} = (1 - 0.5) \\cdot g_{M, \\text{base}} = 0.5 \\cdot (12 \\times 10^{-9}\\ \\mathrm{S}) = 6 \\times 10^{-9}\\ \\mathrm{S}$$\n\nThe leak conductance, $g_L$, and membrane capacitance, $C_m$, remain unchanged. The new total conductance, $g_{tot, \\text{new}}$, is:\n$$g_{tot, \\text{new}} = g_L + g_{M, \\text{new}} = 8 \\times 10^{-9}\\ \\mathrm{S} + 6 \\times 10^{-9}\\ \\mathrm{S} = 14 \\times 10^{-9}\\ \\mathrm{S}$$\n\nThe new input resistance, $R_{in, \\text{new}}$, is the reciprocal of the new total conductance:\n$$R_{in, \\text{new}} = \\frac{1}{g_{tot, \\text{new}}} = \\frac{1}{14 \\times 10^{-9}\\ \\mathrm{S}} = \\frac{10^9}{14}\\ \\Omega = \\frac{500}{7} \\times 10^6\\ \\Omega$$\nIn megaohms, this is $\\frac{500}{7}\\ \\mathrm{M\\Omega} \\approx 71.42857\\ \\mathrm{M\\Omega}$.\n\nThe new membrane time constant, $\\tau_{m, \\text{new}}$, is:\n$$\\tau_{m, \\text{new}} = R_{in, \\text{new}} \\cdot C_m = \\left(\\frac{500}{7} \\times 10^6\\ \\Omega\\right) \\cdot (150 \\times 10^{-12}\\ \\mathrm{F}) = \\frac{75000}{7} \\times 10^{-6}\\ \\mathrm{s} = \\frac{75}{7} \\times 10^{-3}\\ \\mathrm{s}$$\nIn milliseconds, this is $\\frac{75}{7}\\ \\mathrm{ms} \\approx 10.7142857\\ \\mathrm{ms}$.\n\nThe problem asks for the change (new minus baseline) in input resistance, $\\Delta R_{in}$, and membrane time constant, $\\Delta \\tau_m$.\n\nThe change in input resistance is:\n$$\\Delta R_{in} = R_{in, \\text{new}} - R_{in, \\text{base}} = \\left(\\frac{500}{7} - 50\\right)\\ \\mathrm{M\\Omega} = \\left(\\frac{500 - 350}{7}\\right)\\ \\mathrm{M\\Omega} = \\frac{150}{7}\\ \\mathrm{M\\Omega}$$\nNumerically, $\\Delta R_{in} \\approx 21.42857\\ \\mathrm{M\\Omega}$. Rounded to four significant figures, the change in input resistance is $21.43\\ \\mathrm{M\\Omega}$.\n\nThe change in membrane time constant is:\n$$\\Delta \\tau_m = \\tau_{m, \\text{new}} - \\tau_{m, \\text{base}} = \\left(\\frac{75}{7} - 7.5\\right)\\ \\mathrm{ms} = \\left(\\frac{75}{7} - \\frac{15}{2}\\right)\\ \\mathrm{ms} = \\left(\\frac{150 - 105}{14}\\right)\\ \\mathrm{ms} = \\frac{45}{14}\\ \\mathrm{ms}$$\nNumerically, $\\Delta \\tau_m \\approx 3.2142857\\ \\mathrm{ms}$. Rounded to four significant figures, the change in membrane time constant is $3.214\\ \\mathrm{ms}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n21.43 & 3.214\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Beyond altering a neuron's intrinsic properties, cholinergic signals also regulate the communication between neurons by acting on presynaptic terminals. This exercise explores the function of M2 muscarinic autoreceptors, a critical negative feedback system that controls acetylcholine release. By working through this problem, you will connect the molecular cascade of Gi/o protein signaling to its physiological consequences on calcium dynamics, release probability ($p$), and short-term synaptic plasticity .",
            "id": "5007946",
            "problem": "A cholinergic axon makes a single synapse onto a postsynaptic neuron whose response is mediated by nicotinic acetylcholine receptors. The presynaptic terminal expresses M2 muscarinic autoreceptors that couple to the pertussis toxin-sensitive G inhibitory/o class (Gi/o) of heterotrimeric guanine nucleotide-binding proteins. A paired-pulse stimulation protocol is used to evoke two excitatory postsynaptic currents (EPSCs; first and second) separated by an inter-pulse interval of $50\\,\\mathrm{ms}$, and the paired-pulse ratio (PPR) is computed as $\\mathrm{PPR} = \\mathrm{EPSC}_2 / \\mathrm{EPSC}_1$. \n\nStarting from the following foundational facts:\n- Evoked neurotransmitter release follows a quantal relationship in which mean synaptic response amplitude is $A = N p q$, where $N$ is the number of release-ready vesicles, $p$ is the vesicular release probability, and $q$ is the quantal size.\n- Vesicular release probability $p$ depends steeply on presynaptic calcium concentration $[\\mathrm{Ca}^{2+}]$ in the release microdomain, often approximated by a power law $p \\propto ([\\mathrm{Ca}^{2+}]_{\\text{micro}})^n$ with $n$ in the range $3$ to $4$, and $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$ primarily reflects the current through voltage-gated N-type calcium channels during an action potential.\n- Short-term plasticity over tens of milliseconds arises from the interplay of residual calcium (which can transiently increase $p$ for the second pulse) and vesicle depletion (which can transiently decrease the effective $N$ and/or $p$ for the second pulse), making $\\mathrm{PPR}$ inversely related to baseline $p$ in many central synapses.\n\nA selective M2 muscarinic agonist is applied to activate the autoreceptors, and, in a separate condition, a selective M2 muscarinic antagonist is applied to block them. Which statements below are most consistent with the mechanism by which M2 autoreceptors, via Gi/o signaling, reduce presynaptic acetylcholine release by inhibiting N-type calcium channels, and with the expected consequences for paired-pulse measurements at $50\\,\\mathrm{ms}$? Select all that apply.\n\nA. Activating M2 autoreceptors reduces N-type calcium channel activity, lowers presynaptic $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$, decreases $p$ and the first EPSC amplitude, and increases $\\mathrm{PPR}$ because reduced vesicle depletion and preserved residual calcium-dependent facilitation make $\\mathrm{EPSC}_2$ relatively larger than $\\mathrm{EPSC}_1$.\n\nB. Activating M2 autoreceptors increases calcium influx via Gq/11 and phospholipase C, raises $p$, and thereby decreases $\\mathrm{PPR}$.\n\nC. The dominant effect of M2 autoreceptor activation is postsynaptic; it decreases nicotinic receptor conductance without changing presynaptic calcium entry, so $\\mathrm{PPR}$ remains unchanged even though both EPSCs become smaller.\n\nD. Blocking M2 autoreceptors with an antagonist increases N-type calcium current and $p$, producing a larger first EPSC and a decrease in $\\mathrm{PPR}$ due to enhanced vesicle depletion that disproportionately reduces $\\mathrm{EPSC}_2$ relative to $\\mathrm{EPSC}_1$.",
            "solution": "The problem asks to identify the statements that are most consistent with the known mechanism of M2 muscarinic autoreceptor signaling and its impact on paired-pulse plasticity at a cholinergic synapse. The validation of the problem statement confirms that it is scientifically sound, well-posed, and based on established principles of neurophysiology.\n\nThe core principles provided are:\n1.  The M2 autoreceptor is presynaptic and coupled to the Gi/o class of G-proteins. The question specifies that this signaling reduces presynaptic acetylcholine release by inhibiting N-type calcium channels.\n2.  Neurotransmitter release is quantal: mean excitatory postsynaptic current (EPSC) amplitude is $\\mathrm{EPSC} = N p q$, where $N$ is the number of release-ready vesicles, $p$ is the vesicular release probability, and $q$ is the quantal size.\n3.  Release probability $p$ is a steep function of the presynaptic calcium concentration in the microdomain, $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$, which is primarily determined by calcium influx through N-type channels.\n4.  The paired-pulse ratio, $\\mathrm{PPR} = \\mathrm{EPSC}_2 / \\mathrm{EPSC}_1$, is a measure of short-term plasticity and is stated to be inversely related to the initial release probability, $p_1$. This inverse relationship arises from the interplay between vesicle depletion (which causes depression and is more pronounced at high $p$) and residual calcium (which causes facilitation).\n\nLet's analyze the consequences of applying a selective M2 agonist and antagonist based on these principles.\n\n**Effect of a Selective M2 Agonist:**\n1.  Application of an M2 agonist activates the presynaptic M2 autoreceptors.\n2.  Activation of these Gi/o-coupled receptors leads to the inhibition of voltage-gated N-type calcium channels. This is a canonical pathway for Gi/o-mediated presynaptic inhibition.\n3.  Inhibition of N-type calcium channels reduces the influx of $\\mathrm{Ca}^{2+}$ during a presynaptic action potential. This lowers the peak $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$.\n4.  Since $p$ is highly sensitive to $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$ ($p \\propto ([\\mathrm{Ca}^{2+}]_{\\text{micro}})^n$ where $n > 1$), a decrease in calcium influx causes a significant decrease in the initial release probability, $p_1$.\n5.  The amplitude of the first EPSC, $\\mathrm{EPSC}_1 = N p_1 q$, will decrease as a direct result of the reduced $p_1$.\n6.  According to the provided principle that PPR is inversely related to $p_1$, a decrease in $p_1$ will cause an increase in the $\\mathrm{PPR}$. The underlying reason is that with a lower initial $p_1$, fewer vesicles are released by the first pulse, leading to less vesicle depletion. This reduction in paired-pulse depression allows the facilitating effect of residual calcium to become more prominent, making $\\mathrm{EPSC}_2$ relatively larger compared to the diminished $\\mathrm{EPSC}_1$.\n\n**Effect of a Selective M2 Antagonist:**\n1.  Application of an M2 antagonist blocks the M2 autoreceptors. The effect of an antagonist is observable only if there is a baseline level of agonist present. In a synapse that fires repeatedly, the released acetylcholine (ACh) can act on the autoreceptors, creating a tonic (baseline) level of inhibition. An antagonist would block this tonic inhibition.\n2.  Blocking the tonic inhibitory signal from endogenous ACh leads to a disinhibition of the N-type calcium channels.\n3.  This disinhibition results in a larger $\\mathrm{Ca}^{2+}$ influx per action potential compared to the tonic baseline.\n4.  The increased $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$ leads to an increase in the initial release probability, $p_1$.\n5.  The amplitude of the first EPSC, $\\mathrm{EPSC}_1 = N p_1 q$, will increase.\n6.  Following the inverse relationship, the increase in $p_1$ will cause a decrease in the $\\mathrm{PPR}$. This is because a higher $p_1$ enhances vesicle depletion caused by the first pulse, leading to stronger paired-pulse depression. Consequently, $\\mathrm{EPSC}_2$ is disproportionately smaller relative to the now larger $\\mathrm{EPSC}_1$.\n\nNow, we evaluate each option:\n\n**A. Activating M2 autoreceptors reduces N-type calcium channel activity, lowers presynaptic $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$, decreases $p$ and the first EPSC amplitude, and increases $\\mathrm{PPR}$ because reduced vesicle depletion and preserved residual calcium-dependent facilitation make $\\mathrm{EPSC}_2$ relatively larger than $\\mathrm{EPSC}_1$.**\nThis statement perfectly aligns with our derivation of the effects of an M2 agonist. It correctly identifies the signaling cascade (M2 activation $\\rightarrow$ reduced Ca channel activity $\\rightarrow$ lower $[\\mathrm{Ca}^{2+}]_{\\text{micro}}$), the consequence for release ($p$ and $\\mathrm{EPSC}_1$ decrease), and the impact on short-term plasticity (PPR increases). The provided reason for the PPR increase (reduced vesicle depletion) is also correct.\nVerdict: **Correct**.\n\n**B. Activating M2 autoreceptors increases calcium influx via Gq/11 and phospholipase C, raises $p$, and thereby decreases $\\mathrm{PPR}$.**\nThis statement incorrectly identifies the G-protein pathway. The problem explicitly states that M2 receptors couple to Gi/o proteins, which are inhibitory. Gq/11 signaling, which can lead to increased intracellular calcium via phospholipase C and IP3, is characteristic of M1, M3, and M5 receptor subtypes, not M2. Therefore, the premise of increased calcium influx is false.\nVerdict: **Incorrect**.\n\n**C. The dominant effect of M2 autoreceptor activation is postsynaptic; it decreases nicotinic receptor conductance without changing presynaptic calcium entry, so $\\mathrm{PPR}$ remains unchanged even though both EPSCs become smaller.**\nThis statement makes several incorrect claims. First, the problem defines the M2 receptors as *autoreceptors*, which are presynaptic by definition. Second, the proposed mechanism (decreasing nicotinic receptor conductance) is not a known direct effect of M2 receptor signaling. Third, it contradicts the problem's premise that M2 signaling inhibits N-type calcium channels, thus altering presynaptic calcium entry. If the effect were purely postsynaptic (i.e., a change in $q$), $\\mathrm{EPSC}_1$ and $\\mathrm{EPSC}_2$ would be scaled equally, and PPR would indeed be unchanged. However, the mechanism is presynaptic, affecting $p$, which by definition alters PPR.\nVerdict: **Incorrect**.\n\n**D. Blocking M2 autoreceptors with an antagonist increases N-type calcium current and $p$, producing a larger first EPSC and a decrease in $\\mathrm{PPR}$ due to enhanced vesicle depletion that disproportionately reduces $\\mathrm{EPSC}_2$ relative to $\\mathrm{EPSC}_1$.**\nThis statement accurately describes the effect of an M2 antagonist, assuming tonic activation of the autoreceptors by endogenous acetylcholine. Blocking this tonic inhibition disinhibits calcium channels, increasing $p_1$ and $\\mathrm{EPSC}_1$. As per the inverse relationship, the increased $p_1$ leads to a decreased PPR. The stated reason, enhanced vesicle depletion, is the correct biophysical explanation for this effect. This entire causal chain is consistent with the foundational principles.\nVerdict: **Correct**.",
            "answer": "$$\\boxed{AD}$$"
        },
        {
            "introduction": "The effectiveness of synaptic transmission depends not only on neurotransmitter release and receptor activation but also on the precise timing of its removal from the synaptic cleft. This final practice problem moves into a clinical context, examining how we can therapeutically manipulate the cholinergic system at the neuromuscular junction. You will apply principles of enzyme kinetics and pharmacology to calculate a drug dosage that restores function in a disease state, highlighting the practical importance of understanding acetylcholinesterase (AChE) inhibition .",
            "id": "5007957",
            "problem": "A patient with autoimmune reduction of neuromuscular junction nicotinic acetylcholine receptors (nAChRs) exhibits transmission failure at high-frequency stimulation. To restore the neuromuscular safety factor, a clinician plans to prolong the time that acetylcholine (ACh) remains in the synaptic cleft by administering the reversible acetylcholinesterase (AChE) inhibitor pyridostigmine. At the neuromuscular junction, the removal of ACh by AChE is well described by Michaelis–Menten kinetics, and under physiological conditions the instantaneous synaptic ACh concentration remains much less than the Michaelis constant (i.e., $[ \\mathrm{ACh} ] \\ll K_{M}$), so that ACh decay is effectively first order. Pyridostigmine can be modeled as a reversible competitive inhibitor with inhibition constant $K_{I} = 0.30 \\ \\mu\\mathrm{M}$. In the absence of inhibitor, the ACh half-life is $t_{1/2,0} = 1.0 \\ \\mathrm{ms}$. For adequate transmission with reduced nAChR density, the target ACh half-life is $t_{1/2,\\mathrm{target}} = 6.0 \\ \\mathrm{ms}$. However, to avoid depolarization block from prolonged nAChR occupancy and desensitization, the ACh half-life must not exceed $t_{1/2,\\mathrm{max}} = 10.0 \\ \\mathrm{ms}$.\n\nAssume the following for dosing:\n- An intravenous bolus loading dose is given, with instantaneous distribution and negligible protein binding, so that the synaptic interstitial inhibitor concentration equals the plasma concentration immediately after the bolus.\n- The apparent volume of distribution is $V_{d} = 0.50 \\ \\mathrm{L} \\cdot \\mathrm{kg}^{-1}$.\n- The molecular weight of pyridostigmine bromide is $261 \\ \\mathrm{g} \\cdot \\mathrm{mol}^{-1}$.\n\nStarting from the definitions of first-order decay, Michaelis–Menten kinetics, and competitive inhibition, derive the relationship between the ACh half-life and the inhibitor concentration under the condition $[ \\mathrm{ACh} ] \\ll K_{M}$. Then, using this relationship, compute the intravenous loading dose of pyridostigmine in $\\mathrm{mg} \\cdot \\mathrm{kg}^{-1}$ that achieves $t_{1/2,\\mathrm{target}}$ while respecting the depolarization block constraint. Round your final numerical result to three significant figures. Express your final answer in $\\mathrm{mg} \\cdot \\mathrm{kg}^{-1}$.",
            "solution": "The problem is deemed valid as it is scientifically grounded in principles of neuropharmacology and enzyme kinetics, is well-posed with sufficient information for a unique solution, and is expressed in objective, formal language. There are no contradictions, unsound premises, or ambiguities.\n\nThe solution proceeds in two stages: first, the derivation of the relationship between acetylcholine half-life and inhibitor concentration, and second, the calculation of the required drug dose.\n\n**Part 1: Derivation of the Half-Life Relationship**\n\nThe rate of enzymatic cleavage of acetylcholine (ACh) by acetylcholinesterase (AChE), denoted by $v$, is described by the Michaelis-Menten equation:\n$$ v = -\\frac{d[ \\mathrm{ACh} ]}{dt} = \\frac{V_{\\mathrm{max}}[ \\mathrm{ACh} ]}{K_{M} + [ \\mathrm{ACh} ]} $$\nHere, $[ \\mathrm{ACh} ]$ is the substrate concentration, $V_{\\mathrm{max}}$ is the maximum reaction rate, and $K_{M}$ is the Michaelis constant.\n\nThe problem states that under physiological conditions, the synaptic ACh concentration is much less than the Michaelis constant, i.e., $[ \\mathrm{ACh} ] \\ll K_{M}$. This condition allows for simplification of the denominator: $K_{M} + [ \\mathrm{ACh} ] \\approx K_{M}$. The rate equation becomes:\n$$ -\\frac{d[ \\mathrm{ACh} ]}{dt} \\approx \\left(\\frac{V_{\\mathrm{max}}}{K_{M}}\\right) [ \\mathrm{ACh} ] $$\nThis is a first-order decay process. Let's define the first-order rate constant in the absence of an inhibitor as $k_{0} = \\frac{V_{\\mathrm{max}}}{K_{M}}$. The differential equation is then:\n$$ \\frac{d[ \\mathrm{ACh} ]}{dt} = -k_{0} [ \\mathrm{ACh} ] $$\nThe solution to this equation is $[ \\mathrm{ACh} ](t) = [ \\mathrm{ACh} ]_{t=0} \\exp(-k_{0}t)$. The half-life, $t_{1/2,0}$, is the time required for the concentration to fall to half its initial value. Setting $[ \\mathrm{ACh} ](t_{1/2,0}) = \\frac{1}{2}[ \\mathrm{ACh} ]_{t=0}$ gives:\n$$ \\frac{1}{2} = \\exp(-k_{0} t_{1/2,0}) \\implies \\ln\\left(\\frac{1}{2}\\right) = -k_{0} t_{1/2,0} \\implies t_{1/2,0} = \\frac{\\ln(2)}{k_{0}} $$\n\nPyridostigmine is a competitive inhibitor, which means it competes with ACh for the active site of AChE. In the presence of a competitive inhibitor at concentration $[I]$, the enzyme's apparent Michaelis constant, $K_{M,\\mathrm{app}}$, is increased, while $V_{\\mathrm{max}}$ remains unchanged. The relationship is:\n$$ K_{M,\\mathrm{app}} = K_{M} \\left(1 + \\frac{[I]}{K_{I}}\\right) $$\nwhere $K_{I}$ is the inhibition constant for pyridostigmine.\n\nThe rate of ACh hydrolysis in the presence of the inhibitor, $v_{I}$, is:\n$$ v_{I} = -\\frac{d[ \\mathrm{ACh} ]}{dt} = \\frac{V_{\\mathrm{max}}[ \\mathrm{ACh} ]}{K_{M,\\mathrm{app}} + [ \\mathrm{ACh} ]} $$\nAgain, applying the condition $[ \\mathrm{ACh} ] \\ll K_{M}$, and noting that $K_{M,\\mathrm{app}} \\ge K_{M}$, it follows that $[ \\mathrm{ACh} ] \\ll K_{M,\\mathrm{app}}$. The rate equation simplifies to:\n$$ -\\frac{d[ \\mathrm{ACh} ]}{dt} \\approx \\left(\\frac{V_{\\mathrm{max}}}{K_{M,\\mathrm{app}}}\\right) [ \\mathrm{ACh} ] = k_{I} [ \\mathrm{ACh} ] $$\nThe new first-order rate constant, $k_{I}$, is:\n$$ k_{I} = \\frac{V_{\\mathrm{max}}}{K_{M,\\mathrm{app}}} = \\frac{V_{\\mathrm{max}}}{K_{M} \\left(1 + \\frac{[I]}{K_{I}}\\right)} = \\frac{k_{0}}{1 + \\frac{[I]}{K_{I}}} $$\nThe new half-life, $t_{1/2,I}$, is related to $k_{I}$:\n$$ t_{1/2,I} = \\frac{\\ln(2)}{k_{I}} = \\frac{\\ln(2)}{k_{0}} \\left(1 + \\frac{[I]}{K_{I}}\\right) $$\nSubstituting $t_{1/2,0} = \\frac{\\ln(2)}{k_{0}}$, we arrive at the final derived relationship between inhibitor concentration and ACh half-life:\n$$ t_{1/2,I} = t_{1/2,0} \\left(1 + \\frac{[I]}{K_{I}}\\right) $$\nThis equation shows that the ACh half-life increases linearly with the concentration of the competitive inhibitor under these conditions.\n\n**Part 2: Calculation of the Loading Dose**\n\nFirst, we calculate the required plasma concentration of pyridostigmine, $[I]$, to achieve the target half-life. The problem provides:\n- Uninhibited half-life, $t_{1/2,0} = 1.0 \\ \\mathrm{ms}$.\n- Target half-life, $t_{1/2,\\mathrm{target}} = 6.0 \\ \\mathrm{ms}$.\n- Inhibition constant, $K_{I} = 0.30 \\ \\mu\\mathrm{M}$.\n\nUsing the derived relationship, we set $t_{1/2,I} = t_{1/2,\\mathrm{target}}$ and solve for $[I]$:\n$$ 6.0 \\ \\mathrm{ms} = 1.0 \\ \\mathrm{ms} \\left(1 + \\frac{[I]}{0.30 \\ \\mu\\mathrm{M}}\\right) $$\n$$ 6.0 = 1 + \\frac{[I]}{0.30 \\ \\mu\\mathrm{M}} $$\n$$ 5.0 = \\frac{[I]}{0.30 \\ \\mu\\mathrm{M}} $$\n$$ [I] = 5.0 \\times 0.30 \\ \\mu\\mathrm{M} = 1.5 \\ \\mu\\mathrm{M} $$\nThe maximum allowed half-life is $t_{1/2,\\mathrm{max}} = 10.0 \\ \\mathrm{ms}$. Since our target of $6.0 \\ \\mathrm{ms}$ is below this maximum, the calculated concentration is within the therapeutic window.\n\nNext, we calculate the loading dose required to achieve this concentration. The problem states that the plasma concentration, $C_{p}$, is equal to the synaptic inhibitor concentration, $[I]$, after an intravenous bolus. Therefore, the target plasma concentration is $C_{p,\\mathrm{target}} = 1.5 \\ \\mu\\mathrm{M}$.\n\nWe must convert this molar concentration to a mass concentration ($\\mathrm{mg} \\cdot \\mathrm{L}^{-1}$) using the molecular weight ($MW$) of pyridostigmine bromide, $MW = 261 \\ \\mathrm{g} \\cdot \\mathrm{mol}^{-1}$.\n$$ C_{p,\\mathrm{target}} = 1.5 \\ \\mu\\mathrm{mol} \\cdot \\mathrm{L}^{-1} = 1.5 \\times 10^{-6} \\ \\mathrm{mol} \\cdot \\mathrm{L}^{-1} $$\n$$ C_{p,\\mathrm{target}} = (1.5 \\times 10^{-6} \\ \\mathrm{mol} \\cdot \\mathrm{L}^{-1}) \\times (261 \\ \\mathrm{g} \\cdot \\mathrm{mol}^{-1}) = 3.915 \\times 10^{-4} \\ \\mathrm{g} \\cdot \\mathrm{L}^{-1} $$\nConverting grams to milligrams ($1 \\ \\mathrm{g} = 1000 \\ \\mathrm{mg}$):\n$$ C_{p,\\mathrm{target}} = (3.915 \\times 10^{-4} \\ \\mathrm{g} \\cdot \\mathrm{L}^{-1}) \\times (1000 \\ \\mathrm{mg} \\cdot \\mathrm{g}^{-1}) = 0.3915 \\ \\mathrm{mg} \\cdot \\mathrm{L}^{-1} $$\n\nThe loading dose per kilogram of body weight is determined by the target plasma concentration and the apparent volume of distribution, $V_{d} = 0.50 \\ \\mathrm{L} \\cdot \\mathrm{kg}^{-1}$. The dose is the amount of drug that must be administered to achieve a certain concentration throughout its volume of distribution.\n$$ \\mathrm{Dose\\ per\\ kg} = C_{p,\\mathrm{target}} \\times V_{d} $$\n$$ \\mathrm{Dose\\ per\\ kg} = (0.3915 \\ \\mathrm{mg} \\cdot \\mathrm{L}^{-1}) \\times (0.50 \\ \\mathrm{L} \\cdot \\mathrm{kg}^{-1}) $$\n$$ \\mathrm{Dose\\ per\\ kg} = 0.19575 \\ \\mathrm{mg} \\cdot \\mathrm{kg}^{-1} $$\n\nFinally, rounding the result to three significant figures as requested:\n$$ \\mathrm{Dose\\ per\\ kg} \\approx 0.196 \\ \\mathrm{mg} \\cdot \\mathrm{kg}^{-1} $$",
            "answer": "$$\\boxed{0.196}$$"
        }
    ]
}